Guardant Health (NASDAQ:GH) Insider Sells 20,000 Shares

Guardant Health, Inc. (NASDAQ:GH) insider John Saia sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the sale, the insider directly owned 45,950 shares of the company’s stock, valued at $4,894,134.50. The trade was a 30.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Guardant Health Trading Up 0.8%

NASDAQ GH traded up $0.94 during trading on Friday, hitting $118.95. The company had a trading volume of 2,633,856 shares, compared to its average volume of 2,090,416. The company’s fifty day moving average is $90.53 and its 200-day moving average is $98.79. Guardant Health, Inc. has a one year low of $36.36 and a one year high of $121.01. The company has a market cap of $15.77 billion, a price-to-earnings ratio of -35.09 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. During the same quarter last year, the firm earned ($0.62) earnings per share. The company’s quarterly revenue was up 39.4% on a year-over-year basis. As a group, equities analysts anticipate that Guardant Health, Inc. will post -2.92 EPS for the current year.

Hedge Funds Weigh In On Guardant Health

Large investors have recently made changes to their positions in the business. V Square Quantitative Management LLC bought a new stake in shares of Guardant Health in the 4th quarter worth approximately $27,000. Chesapeake Asset Management LLC bought a new position in Guardant Health during the 4th quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Guardant Health during the 4th quarter valued at approximately $31,000. Elyxium Wealth LLC purchased a new position in Guardant Health during the fourth quarter valued at $35,000. Finally, Parallel Advisors LLC boosted its holdings in Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GH has been the topic of several research reports. Canaccord Genuity Group lifted their price objective on Guardant Health from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, February 20th. BTIG Research raised their target price on Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Raymond James Financial restated an “outperform” rating and set a $129.00 price target on shares of Guardant Health in a research report on Monday, February 23rd. Leerink Partners upped their price target on Guardant Health from $170.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, February 20th. Finally, Wells Fargo & Company increased their price objective on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Nineteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $129.00.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.